GlassScriptPhysician profile
Amy B Schiffman
NPI 1972864064
$25,322.04
in general payments reported to CMS, 2019-2025
29 companies · $2,658 in 2025
The $2,658 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $413 · 2020: $878 · 2021: $5,575 · 2022: $6,471 · 2023: $5,271 · 2024: $4,056 · 2025: $2,658.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,750 · Food and Beverage: $5,127 · Consulting Fee: $96.47 · Education: $11.66.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,750.00 |
| Food and Beverage | $5,126.84 |
| Consulting Fee | $96.47 |
| Education | $11.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $20,201.82 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Glaxosmithkline, LLC. | $709.97 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Takeda Pharmaceuticals U.S.A., INC. | $687.67 | 2021-2025 | Hyqvia, Glassia, Cuvitru |
| Regeneron Healthcare Solutions, INC. | $574.89 | 2021-2025 | Dupixent |
| Amgen INC. | $502.37 | 2021-2025 | Tezspire |
| Alk-Abello, INC | $360.26 | 2019-2022 | |
| Genzyme Corporation | $353.70 | 2022-2025 | |
| Csl Behring | $260.39 | 2021-2025 | Hizentra |
| Blueprint Medicines Corporation | $232.10 | 2023-2024 | Ayvakit |
| Genentech USA, INC. | $232.10 | 2020-2025 | Xolair |
| Novartis Pharmaceuticals Corporation | $212.01 | 2024-2025 | |
| Incyte Corporation | $165.94 | 2021-2023 | Opzelura |
| Pfizer INC. | $119.31 | 2021-2025 | |
| Biocryst US Sales Co., LLC | $117.28 | 2021 | |
| Adma Biomanufacturing LLC | $96.47 | 2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharming Healthcare, INC. | $88.09 | 2022-2025 | Ruconest |
| Kaleo, INC. | $86.61 | 2020-2022 | |
| Grifols USA, LLC | $71.86 | 2021-2025 | Xembify |
| Ars Pharmaceuticals Operations, INC. | $42.56 | 2025 | Neffy |
| Aimmune Therapeutics, INC. | $35.99 | 2022 | |
| Gc Biopharma USA, INC. | $24.59 | 2025 | Alyglo |
| Leo Pharma INC. | $21.63 | 2022 | |
| Circassia INC. | $18.73 | 2021 | |
| Merck Sharp & Dohme LLC | $18.28 | 2023 | |
| Cycle Pharmaceuticals INC | $18.17 | 2025 | Sajazir |
| Galderma Laboratories, L.P. | $17.92 | 2025 | Nemluvio |
| Octapharma USA, INC. | $17.66 | 2024 | Panzyga |
| Esperion Therapeutics, INC. | $16.85 | 2025 | Nexletol |
| Bio Products Laboratory USA, INC. | $16.82 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Schiffman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.